Radiobiology Research Institute, Churchill Hospital, Headington, Oxford
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths amongst men. Prostate cancer is a highly heterogeneous disease with variable clinical outcomes. Defining the transition from benign to malignant tissue and understanding genetic changes within tumours is fundamental to improve early diagnosis of cancer.
My research focuses on the understanding of the cellular mechanisms of prostate cancer progression and metastases development. I joined NDS to work on the Spatial Prostate Assessment and Circulating Environment (SPACE) study, a translational research programme based on the identification of drivers of progression in localised prostate cancer, incorporating spatial transcriptomics of whole prostate and tracking of cancer clonal evolution.
I am also focused on the relationships between ion channels and androgen receptor in pre-clinical models and clinical samples, using in particular organotypic culture. Indeed, understand the molecular mechanisms underlying the biology of androgen receptor will provide essential insights on tumour progression, response to treatments and will allow to develop tailored therapies.